Healthcast Ep6: New FDA-approved infusion drugs for early-stage Alzheimer’s

Описание: 00:00 Opening and Introductions
1:52 Therapies for patients with Alzheimer's disease - Lecanemab and Donanemab
3:19 Assessment at Stony Brook
4:00 What does plaque do to the brain?
5:00 Medications
6:55 Signs and when to get a cognitive assessment
7:30 Early Stage Alzheimer's
8:55 Aging population and the increase in patients diagnosed with Alzheimer's
10:00 The value of an academic medical center
12:40 Treatment criteria
13:25 Prevalence in men v. women and genetic predisposition
14:30 The Stony Brook Center for Healthy Aging (CHA)
16:08 Therapies administered at Stony Brook
17:45 Results, feedback and outlook
18:35 Advancements in therapies for Alzheimer's disease
20:40 Clinical trials
21:25 How to be assessed and treated at Stony Brook
24:18 The future of treatment for Alzheimer's disease
25:28 Closing Remarks

Lecanemab (Leqembi®) and donanemab (Kisunla®) are two new FDA-approved drugs, administered intravenously, that can slow cognitive decline in people diagnosed with early-stage Alzheimer’s. While not a cure, they can slow the progression of the disease and are available at the Stony Brook Center of Excellence for Alzheimer’s Disease, one of only 10 such centers in New York State and the only one on Long Island. Learn how these infusion drugs work, and how to find out if you or a loved one qualify for treatment, while also learning about other services, resources and more that Stony Brook Medicine has to offer to help Long Island’s aging population.

Experts:
Jolene Knight, NP
Nikhil Palekar, MD

*DISCLAIMER: The information provided in this podcast is for educational and informational purposes only and is not intended as a substitute for professional medical advice, diagnosis or treatment. If you think you may have a medical emergency, call your doctor or emergency services immediately.